CCSN Survey on Rituxan (Rituximab)

The purpose of this survey is to provide us with the needed insights and perspectives about the use of Rituxan (Rituximab) for the treatment of patients with Philadelphia chromosome-negative, CD20 antigen positive, B-cell precursor acute lymphoblastic leukemia in adults. Our survey is open until Monday, Feb.27, 2017, as our submission is due to pCODR on Feb. 28.

Click here to complete the survey.